Add To Watchlist
Share URL
About The Company
Description
Biophytis S.A.
Read More
Overview
Value
12
Growth
35
Health
22
Management
50
Analyst Opinion
51
Total
34
All Scores Out Of 100
Best Features
- Low preportion of income is paid as dividend
Risk Factors
- Overvalued on cashflow basis
- Earnings growth has slowed down recently
- Income is not covering expenditure and investment
- Earnings are negative
- There is a history of diluting shareholders
- Has a high level of debt
- Poor overall financial health
- No margin of safety at their current market price
- Poor earnings and cashflow growth
- Cashflow is growing faster than revenue
Market Peers
ALBPS.PA
Key Figures
PE Ratio (TTM)
N/A
Margin Of Safety (DCF)
-18.37%
Revenue Growth (5 Year Average)
N/A
Ratings Consensus
Neutral
Share Buybacks
-106.34%
Dividend Yeild (TTM)
N/A
Valuation
Value Score
12
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: N/A✘
Current Price: 0 EUR
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
N/Ax
Free Cashflow Yeild
-211.02%
PE/Earnings Growth
N/A
Price/Book
1.39x
Growth
Growth Score
35
- ✔ Revenue growth has improved this yeara
- ✔ 5 Year Average Earnings growth of 15.84% is higher than the market average (14.48%)
- ✘ 5 Year Average Revenue growth of N/A is lower than the market average (10.97%)
- ✘ Earnings growth has slowed this year
- ✘ 5 Year Average Free Cashflow growth of 0.74% is lower than the market average (12.35%)
- ✘ Free Cashflow growth has slowed this year
Revenue Growth
N/A
Earnings Growth
15.84%
Cashflow Growth
0.74%
Health
Health Score
22
Altman Z Score
N/A
Piostroski Score
N/A
Debt/Equity
2.70x
Current Assets/Liabilities
1.37x
Free Cashflow/Total Debt
N/Ax
Debt/Capital
0.49x
Management
Management Score
50
Average Buybacks/Dilution
-106.34%
Recent Buybacks/Dilution
72.44%
5 Year Price Volitility
79.74%
Return On Assets
-146.24%
Return On Capital Employed
-44.09%
Return On Equity
-929.56%
Return On Free Cashflow
526.21%
Return On Investments
-4045.09%
Analysts
Analyst Opinion
51
- ✔ Ratings consensus is Neutral
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Biophytis S.A.
Currency
EUR
Beta
1.34745
Vol Avg
2426308
Ceo
Mr. Stanislas Veillet
Cik
Cusip
F52042102
Exchange
Paris
Full Time Employees
26
Industry
Biotechnology
Sector
Healthcare
Ipo Date
2015-07-13
Address
14 avenue de l'Opera
City
Paris
State
ILE-DE-FRANCE
Country
FR
Zip
75005
Phone
33141836600
All financial data provided by FMP